AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04792671 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sociodemographic variables
Description: age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.
Study NCT04792671 — intervention group
Intervention type: BEHAVIORAL
Intervention: Family affluence scale (FAS)
Description: a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.
Study NCT04792671 — intervention group
Intervention type: BEHAVIORAL
Intervention: Edinburgh postnatal depression scale (EPDS)
Description: s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed
Study NCT04792671 — intervention group
Intervention type: BEHAVIORAL
Intervention: Symptom Checklist 90 SCL 90:
Description: is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed
Study NCT04930042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
Study NCT04930042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVT04
Description: AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
Study NCT03042169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Chemotherapy
Description: Standard chemotherapy regiments according to risk of recurrence
Study NCT03042169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.
Study NCT03042169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy
Description: Chemotherapy should be restarted between D1 and D30 post-randomization
Study NCT03042169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Description: Chemotherapy should be restarted between D1 and D30 post-randomization
Study NCT05997823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotape
Description: The button hole technique was used for area correction during the KT application (Figure 1). Two I-tapes were applied, one from the medial epicondyle to the proximal phalanx on the palmar side and the other from the lateral epicondyle to the proximal phalanx on the dorsal side. The area where the phalanges are located was marked, and two hole was drilled in the center.After cleaning the skin with alcohol, the tape to be applied to the palmar side was passed over the 3rd and 4th fingers, and the patient was asked to perform radial deviation and wrist extension
Study NCT05997823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercises
Description: home exercises
Study NCT05997823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercises
Description: home exercises
Study NCT05210101 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sotrovimab
Description: Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
Study NCT05890690 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urea
Description: Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g.
Study NCT05890690 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®.
Study NCT05368402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: The two daily oral doses of ladarixin (400 mg each dose) will be administered at about a 12-hour interval (morning and evening; ideally between 6:30/11:30 and 18:30/23:30). At each administration, 2 capsules will be swallowed with a glass of water, at least 2 hours apart from breakfast or dinner
Study NCT05368402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered with the same ladarixin schedule.
Study NCT05222438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loncastuximab tesirine
Description: loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
Study NCT05724628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Subjects will receive surgery (using 3 port Laparoscopic appendectomy) to remove appendix
Study NCT05724628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics (IV transitioned to oral)
Description: Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin
Study NCT04653753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kneeSOFT500
Description: At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
Study NCT04761081 — intervention group
Intervention type: BEHAVIORAL
Intervention: Habitual physical activity assessment
Description: 7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
Study NCT05448326 — intervention group
Intervention type: OTHER
Intervention: Questionnaire to assess expectations of a diagnosis
Description: Duration 45 minutes
Study NCT05448326 — intervention group
Intervention type: OTHER
Intervention: Questionnaire to assess understanding of previously reported results and expectations of a diagnosis
Description: Duration 30 minutes
Study NCT05448326 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample +/- skin biopsy
Description: 8 ml of blood biopsy: size 3 to 5 mm
Study NCT06174376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE Synthetic Cornea Device
Description: Treatment with GORE Synthetic Cornea Device
Study NCT04913727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging before the procedure
Description: CMR image acquisition with previously mentioned analysis
Study NCT04913727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral edge-to-edge repair.
Description: Included patients will undergo Transcatheter mitral edge-to-edge repair.
Study NCT06471946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT
Description: Patients were treated by VA Conditioning Regimen Allo-HSCT:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9
Study NCT05961410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag olamine
Description: Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
Study NCT05893004 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Headache Screening Questionnaire
Description: The Dutch Headache Screening Questionnaire (HSQ) is the only screening questionnaire based on ICHD-3 which has at least moderate confidence in its criterion validity according to GRADE. The HSQ has already been translated into Portuguese and validated5. The HSQ has only 8 items and requires little time to complete. Due to its good sensitivity, the HSQ screening questionnaire is particularly well suited to exclude migraine.
Study NCT05666128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-6277
Description: HD-6277 100mg
Study NCT05666128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-6277
Description: HD-6277 50mg
Study NCT05666128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05178641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninjamas Pyjama Pants
Description: Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.
Study NCT05178641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant's Overnight Current Standard of Care
Description: Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
Study NCT06647901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG (Indocyanine Green)
Description: Patients will be receive intravenously administrated at a dose of 2 mg/kg on the day before surgery. The drug was dissolved into 250 mL of normal saline and administered using a light-proof infusion apparatus. The time course of administration was 60 min. NIR imaging will be performed during surgery to help identify small tumor residuals.
Study NCT06647615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR headset
Description: The VR portion of the study will last for 8 weeks. You will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like.
Study NCT05821296 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Crystal Peel
Description: 3 applications performed by a dermatologist.
Study NCT06511570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabirnetug (ACU193)
Description: sabirnetug by intravenous infusion
Study NCT06511570 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sabirnetug + rHuPH20
Description: sabirnetug + rHuPH20 by subcutaneous injection
Study NCT05420857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground Visual Biofeeback
Description: Subjects participate in biofeedback training for 3 6-minute bouts in a single session.
Study NCT04939311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201
Description: One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
Study NCT04939311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
Study NCT05429359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPET: CardioPulmonary Exercise Test for CSII users
Description: * Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* CSII users: 100% basal
Study NCT05429359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEX1: Aerobic Exercise Test 1 for CSII users
Description: * 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -2h target 150 mg/dL
Study NCT05429359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEX2: Aerobic Exercise Test 2 for CSII users
Description: * 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -1h target 150 mg/dL
Study NCT05429359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPET: CardioPulmonary Exercise Test for MDI users
Description: * Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* MDI users: 100% basal
Study NCT05429359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEX1: Aerobic Exercise Test 1 for MDI users
Description: * 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 50% basal
Study NCT05429359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEX2: Aerobic Exercise Test 2 for MDI users
Description: * 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 80% basal
Study NCT05967676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Turkish adaptation, validity and reliability
Description: This study was conducted as test-retest design and the psychometric properties of PRIA-RS were examined in injured athletes
Study NCT04927039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5ml of inhaled normal saline
Description: After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
Study NCT04927039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline
Description: After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
Study NCT04473820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant spray
Description: The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
Study NCT04473820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-Prilocaine cream
Description: A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
Study NCT04880161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Inhaled Ampion
Study NCT04880161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo
Study NCT06611098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscosupplements
Description: intra-articular injection
Study NCT06611098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viscosupplements
Description: intra-articular injection
Study NCT06673095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06673095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06673095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision
Description: Undergo narrow margin excision
Study NCT06673095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision
Description: Undergo wide margin excision
Study NCT05691608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Solid tumor and CT DNA
Description: Biopsy and blood sample
Study NCT04864158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSA-group
Description: Reverse total shoulder arthroplasty followed by standard rehabilitation.
Study NCT06673095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06673095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05314556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Description: Additional group psychotherapy for patients with narcolepsy type 1 with standard medication
Study NCT05623137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Description: A dual-channel TENS stimulator will be used (ECS300A; Neurotrac, Verity Medical LTD, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
Study NCT05623137 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acu-TENS
Description: A dual-channel TENS stimulator will be used (ITO Physiotherapy \& Rehabilitation, Co, Ltd, Tokyo, Japan). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
Study NCT05623137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHP
Description: SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
Study NCT05623137 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHP
Description: SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
Study NCT05312437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interruptive Alert, CDS
Description: Experimental: CDS Intervention Adult patients in the highest predicted risk tier (>=2% predicted risk) at the time visit registration (aka check-in).~The Intervention would then be described as:~Physicians review a Best Practice Advisory describing the patient's risk and choose from the following options:~1. Document face-to-face suicide risk screening with the Columbia Suicide Severity Rating Scale (CDS complete once the CSSRS is complete)~2. Agree to screen using an alternative method chosen at the clinician's discretion (CDS complete)~3. Disagree with alert and provide a rationale for disagreement (CDS complete)~4. Indicate suicide risk face-to-face screening has already occurred (CDS complete)~5. Dismiss the alert. The alert will be available in Epic Storyboard persistently until acted on further. The Storyboard functionality after dismissal is identical to the Passive Prompt, CDS intervention (below)
Study NCT05312437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Prompt, CDS
Description: Adult patients in the highest predicted risk tier (>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm.
Study NCT06345937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Experimental: guidelines-based physical activity
Description: Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.